AN2 Therapeutics Enters into Collaboration with GSK to Advance Boron-Based Therapies for Tuberculosis
Tuesday, November 11, 2025
AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).
The Gates Foundation will provide an additional year of funding to support AN2’s work within this partnership.
Tuberculosis remains one of the world’s most severe health challenges, affecting over a quarter of the global population and causing more than 1.25 million deaths each year. The collaboration aims to develop boron-based leucyl-tRNA synthetase (LeuRS) inhibitors, a new class of compounds targeting novel mechanisms not accessible through conventional carbon-based chemistry.
AN2’s boron chemistry platform has shown potential in developing drugs for infectious diseases such as nontuberculous mycobacterial (NTM) lung disease and TB. The same validated LeuRS target forms the basis of several compounds, including epetraborole (in development for NTM lung disease), ganfeborole (in development for TB), and tavaborole, an FDA-approved antifungal.
This collaboration builds on previous work between AN2’s team and GSK’s Global Health research and development group. It represents a joint effort to explore innovative approaches that could help address the growing burden of TB, particularly in low-income countries.
By combining AN2’s expertise in boron-based drug discovery with GSK’s global health capabilities and continued support from the Gates Foundation, the initiative aims to contribute to the development of new and effective therapies for tuberculosis.
Source: businesswire.com
